A rare cutaneous adverse effect secondary to cabozantinib therapy

Cabozantinib is a tyrosine kinase inhibitor which is increasingly being used for the treatment of metastatic renal cell cancer. Skin toxicity such as palmar-plantar erythrodysesthesia is not uncommon with such agents. However, bullous skin reactions are not common and we report the case of a patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Growcott, Siona, Banner, Alexandra, Bray, Adam, Hilman, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252307/
https://www.ncbi.nlm.nih.gov/pubmed/30487990
http://dx.doi.org/10.1093/omcr/omy105
_version_ 1783373232239280128
author Growcott, Siona
Banner, Alexandra
Bray, Adam
Hilman, Serena
author_facet Growcott, Siona
Banner, Alexandra
Bray, Adam
Hilman, Serena
author_sort Growcott, Siona
collection PubMed
description Cabozantinib is a tyrosine kinase inhibitor which is increasingly being used for the treatment of metastatic renal cell cancer. Skin toxicity such as palmar-plantar erythrodysesthesia is not uncommon with such agents. However, bullous skin reactions are not common and we report the case of a patient with metastatic renal cell cancer who experienced such cutaneous toxicity.
format Online
Article
Text
id pubmed-6252307
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62523072018-11-28 A rare cutaneous adverse effect secondary to cabozantinib therapy Growcott, Siona Banner, Alexandra Bray, Adam Hilman, Serena Oxf Med Case Reports Case Report Cabozantinib is a tyrosine kinase inhibitor which is increasingly being used for the treatment of metastatic renal cell cancer. Skin toxicity such as palmar-plantar erythrodysesthesia is not uncommon with such agents. However, bullous skin reactions are not common and we report the case of a patient with metastatic renal cell cancer who experienced such cutaneous toxicity. Oxford University Press 2018-11-26 /pmc/articles/PMC6252307/ /pubmed/30487990 http://dx.doi.org/10.1093/omcr/omy105 Text en © The Author(s) 2018. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Growcott, Siona
Banner, Alexandra
Bray, Adam
Hilman, Serena
A rare cutaneous adverse effect secondary to cabozantinib therapy
title A rare cutaneous adverse effect secondary to cabozantinib therapy
title_full A rare cutaneous adverse effect secondary to cabozantinib therapy
title_fullStr A rare cutaneous adverse effect secondary to cabozantinib therapy
title_full_unstemmed A rare cutaneous adverse effect secondary to cabozantinib therapy
title_short A rare cutaneous adverse effect secondary to cabozantinib therapy
title_sort rare cutaneous adverse effect secondary to cabozantinib therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252307/
https://www.ncbi.nlm.nih.gov/pubmed/30487990
http://dx.doi.org/10.1093/omcr/omy105
work_keys_str_mv AT growcottsiona ararecutaneousadverseeffectsecondarytocabozantinibtherapy
AT banneralexandra ararecutaneousadverseeffectsecondarytocabozantinibtherapy
AT brayadam ararecutaneousadverseeffectsecondarytocabozantinibtherapy
AT hilmanserena ararecutaneousadverseeffectsecondarytocabozantinibtherapy
AT growcottsiona rarecutaneousadverseeffectsecondarytocabozantinibtherapy
AT banneralexandra rarecutaneousadverseeffectsecondarytocabozantinibtherapy
AT brayadam rarecutaneousadverseeffectsecondarytocabozantinibtherapy
AT hilmanserena rarecutaneousadverseeffectsecondarytocabozantinibtherapy

Ejemplares similares